7.25
Schlusskurs vom Vortag:
$6.86
Offen:
$6.97
24-Stunden-Volumen:
28,314
Relative Volume:
0.14
Marktkapitalisierung:
$42.48M
Einnahmen:
$100.44M
Nettoeinkommen (Verlust:
$-133.16M
KGV:
-0.2814
EPS:
-25.76
Netto-Cashflow:
$-94.85M
1W Leistung:
+5.07%
1M Leistung:
-15.60%
6M Leistung:
-25.41%
1J Leistung:
-53.97%
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Firmenname
Atara Biotherapeutics Inc
Sektor
Branche
Telefon
805-623-4211
Adresse
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Vergleichen Sie ATRA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ATRA
Atara Biotherapeutics Inc
|
7.25 | 42.48M | 100.44M | -133.16M | -94.85M | -25.76 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
504.77 | 129.62B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
666.87 | 72.91B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
604.96 | 36.76B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
241.76 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
259.19 | 27.86B | 3.32B | -860.46M | -1.04B | -8.32 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-11-09 | Herabstufung | Evercore ISI | Outperform → In-line |
2023-11-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2023-11-09 | Herabstufung | Mizuho | Buy → Neutral |
2022-07-20 | Herabstufung | Citigroup | Neutral → Sell |
2022-07-13 | Herabstufung | JP Morgan | Overweight → Neutral |
2022-07-13 | Herabstufung | Stifel | Buy → Hold |
2022-05-10 | Herabstufung | Citigroup | Buy → Neutral |
2021-05-13 | Hochstufung | JP Morgan | Neutral → Overweight |
2020-12-09 | Herabstufung | Citigroup | Buy → Neutral |
2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
2020-11-10 | Bestätigt | H.C. Wainwright | Buy |
2020-06-30 | Eingeleitet | Evercore ISI | Outperform |
2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
2020-04-23 | Hochstufung | Citigroup | Neutral → Buy |
2019-11-08 | Herabstufung | JP Morgan | Overweight → Neutral |
2019-09-27 | Herabstufung | Goldman | Neutral → Sell |
2019-09-16 | Herabstufung | Jefferies | Buy → Hold |
2019-06-04 | Hochstufung | Citigroup | Sell → Neutral |
2019-05-30 | Eingeleitet | ROTH Capital | Buy |
2019-05-23 | Eingeleitet | Stifel | Buy |
2019-01-23 | Eingeleitet | Mizuho | Buy |
2018-04-10 | Eingeleitet | JP Morgan | Overweight |
2018-03-16 | Eingeleitet | Guggenheim | Neutral |
2018-03-05 | Bestätigt | Jefferies | Buy |
2018-02-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
2018-02-15 | Herabstufung | Citigroup | Neutral → Sell |
2018-01-03 | Hochstufung | Citigroup | Sell → Neutral |
2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Atara Biotherapeutics (NASDAQ:ATRA) Given Buy Rating at Canaccord Genuity Group - Defense World
Atara Biotherapeutics: Strategic Focus on Ebvallo BLA Resubmission and Market Position Enhancement - TipRanks
Atara Biotherapeutics: Q4 Earnings Snapshot - The Bakersfield Californian
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Atara Biotherapeutics Faces Potential Liquidation: Strategic Decisions Crucial for Investor Outcomes - TipRanks
Atara Biotherapeutics Reports 2024 Financial Results - TipRanks
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress - BioSpace
Atara Biotherapeutics Inc. (ATRA) reports earnings - Quartz
Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace
Atara Biotherapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Lacklustre Performance Is Driving Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) 27% Price Drop - Simply Wall St
Nguyen AnhCo, CEO of Atara Biotherapeutics, sells $23,307 in stock By Investing.com - Investing.com Australia
Atara biotherapeutics EVP and CFO Eric Hyllengren sells $8,473 in stock By Investing.com - Investing.com South Africa
Atara biotherapeutics EVP and CFO Eric Hyllengren sells $8,473 in stock - Investing.com Australia
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is i - GuruFocus.com
Atara biotherapeutics EVP sells $7,409 in common stock - Investing.com India
Nguyen AnhCo, CEO of Atara Biotherapeutics, sells $23,307 in stock - Investing.com India
Trading (ATRA) With Integrated Risk Controls - Stock Traders Daily
Atara Biotherapeutics Inc To Cut 50% Of Workforce -March 03, 2025 at 05:26 pm EST - Marketscreener.com
Wall Street Analysts Think Atara Biotherapeutics (ATRA) Could Surge 33.03%: Read This Before Placing a Bet - MSN
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
(ATRA) Investment Analysis - Stock Traders Daily
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws - Finansavisen
Cancer Index takes hit in 2024 amid regulatory setbacks, failures - BioWorld Online
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - Longview News-Journal
How the (ATRA) price action is used to our Advantage - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2025-02-10 | Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:ATRA | Press Release - Stockhouse Publishing
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 - BioSpace
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation - Markets Insider
2025-02-09 | Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation | NDAQ:ATRA | Press Release - Stockhouse Publishing
Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip - MSN
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Rating of “Moderate Buy” from Brokerages - Armenian Reporter
Atara Biotherapeutics (NASDAQ:ATRA) Stock Quotes, Forecast and News Summary - Benzinga
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation - Markets Insider
Analysts Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Price Target at $17.75 - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation - Markets Insider
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Wolf Haldenstein Adler Freeman & Herz LLP announces that it - GlobeNewswire
Finanzdaten der Atara Biotherapeutics Inc-Aktie (ATRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):